Citius Pharmaceuticals, Inc.
CTXRAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| D. Boral Capital | maintain | Buy | Mar 11, 2026 |
| D. Boral Capital | maintain | Buy | Dec 4, 2025 |
| D. Boral Capital | maintain | Buy | Aug 13, 2025 |
| D. Boral Capital | maintain | Buy | Jun 30, 2025 |
| D. Boral Capital | maintain | Buy | Jun 10, 2025 |
| D. Boral Capital | maintain | Buy | Jun 9, 2025 |
| Maxim Group | downgrade | Buy →Hold | May 23, 2025 |
| D. Boral Capital | maintain | Buy | May 15, 2025 |
| D. Boral Capital | maintain | Buy | Feb 18, 2025 |
| D. Boral Capital | maintain | Buy | Jan 7, 2025 |
| D. Boral Capital | upgrade | Hold →Buy | Dec 30, 2024 |
| D. Boral Capital | downgrade | Buy →Hold | Nov 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2024 |
| D. Boral Capital | maintain | Buy | Nov 11, 2024 |
| EF Hutton | maintain | Buy | Aug 19, 2024 |
| EF Hutton | maintain | Buy | Aug 8, 2024 |
| EF Hutton | maintain | Buy | Aug 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 29, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jan 18, 2022 |
Earnings History
Next report: Dec 22, 2026 · EPS est. $-0.41| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.34 | $-0.36 | $1.5M | $5.5M |
| May 15, 2026 | $-0.95 | $0.39 | $1.7M | $18.8M |
| Feb 13, 2026 | $-0.38 | $0.43 | $3.9M | $18.0M |
| Dec 26, 2025 | $-0.01 | $-0.43 | $3.9M | $5.8M |
| Aug 12, 2025 | $-0.80 | $-0.51 | — | $1.9M |
| May 14, 2025 | $-1.27 | $-1.08 | — | $5.3M |
| Feb 14, 2025 | $-1.30 | $-1.25 | — | $2.7M |
| Jan 3, 2025 | $-1.50 | $-0.04 | — | $7.1M |
News
Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures CRANFORD, N.J., Nov. 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR) today announced health-related quality of life (HRQoL) results from pivotal Study 302 ( NCT01871727…
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIRÂ Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference CRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one inves…
Shares of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) have been given a consensus recommendation of "Hold" by the five brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to
Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Profitability This table compares Citius Pharmaceuticals and Tarsus
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) has been given a consensus recommendation of "Hold" by the five research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference CRANFORD, N.J.
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today repo…
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering LYMPHIR ordered by 44 institutions since launch CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas…
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.